Mecasermin is a recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons.
- Mechanism
- Curator reviewed · 1 reference
Mecasermin supplies recombinant-DNA-origin IGF-1, which binds to the Type I IGF-1 receptor. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth.
- Primary indication
- For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH.Curator reviewed · 1 structured indication
- Formula / weight
- C331H518N94O101S7 · 7649.0 Da
- First approval
- Canada, 2026 · United States, 2006 · European Union, 2016
- Also known as
- INSULIN-LIKE GROWTH FACTOR 1 · INSULIN-LIKE GROWTH FACTOR I (HUMAN) · Mecasermin recombinant · RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-I · RH-OLIGOPEPTIDE-2
- Code names
- CEP-151 · CG-GF2 · CG-IGF-1 · PV-802
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Mecasermin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account